Few Older Patients Aware of Deprescribing

This article originally appeared here.
Share this content:
Few Older Patients Aware of Deprescribing
Few Older Patients Aware of Deprescribing

FRIDAY, Sept. 22, 2017 (HealthDay News) -- The majority of older patients are aware of medication harms, but far fewer understand deprescribing, according to a brief report published online Sept. 15 in the Journal of the American Geriatrics Society.

Justin P. Turner, Ph.D., from the University of Montreal, and colleagues analyzed data from a survey of community-dwelling adults aged 65 years and older (2,665 total participants; 898 men; mean age, 74.9 years) to determine older adults' awareness of the concept of medication-induced harm.

The researchers found that nearly two-thirds of participants (65.2 percent) were familiar with the concept of medication-induced harms. Nearly half (48 percent) had researched medication-related harms either through the internet (35.5 percent) or from health care professionals (32.2 percent). However, only 6.9 recognized the term deprescribing.

"Health care providers can facilitate patient-initiated deprescribing conversations by providing information on medication harms and using the term 'deprescribing,'" the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »